Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru DEC 2009
    - OnBioVC 2009 Year-in-Review, now available
    - OnBioVC 1Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • business strategy life science

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

KeyNeurotek Pharmaceuticals (Germany) a clinical-stage small molecule company focused on autoimmune and CNS diseases, closed a $10.9M Series C financing. Participants include DVC Deutsche Venture Capital, IBG Beteiligungsgesellschaft and KfW Bankengruppe.

Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.

Psyadon Pharmaceuticals (Germantown, MD) early-stage developer of glutamate transport modulation for CNS indications, closed a $8M Series A financing. Participants include New Enterprise Associates, Aberdare Ventures and Domain Associates.

Knopp Neurosciences (Pittsburgh, PA) early-stage drug discovery and development company focused on amyotrophic lateral sclerosis and other neurological disorders, closed a $27M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

BrainsGate (Israel) development-stage company focused on electrical stimulation for CNS disorders, closed a $27.5M Series C financing. Participants include Johnson & Johnson Development Corp., Agate Medical Investments, Elron Electronic Industries, Pitango Venture Capital, MB Venture Capital and Alice Lab.

« Previous Entries  

to top of page...